Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2015

View Archived Issues

Study of GABA-A receptor signaling in Down syndrome model yields potential treatment strategy

TaiGen initiates phase I/II trial of burixafor in AML

Discovery of a bacterial RNR-targeting antibiotic to combat resistance

Lycera enters clinic with first program, LYC-30937 for IBD

Advanced Proteome Therapeutics reports findings on APC-191 in tumor metastasis

Tamir Biotechnology updates development progress of TMR-004 for Ebola

Novo Nordisk presents pipeline events of first quarter 2015

AstraZeneca discloses novel PI3Kalpha/delta inhibitior

BioLineRx's phase II study of BL-8040 for AML enters expansion stage

Shire and Foundation Fighting Blindness collaborate on autosomal dominant retinitis pigmentosa

New efficacy data presented for the antibody-drug conjugate ASN-004

Isis licenses ISIS-FXIRx to Bayer for prevention of thrombosis

Eisai develops new TLR7 and TLR8 antagonists

GlaxoSmithKline patents PERK inhibitors

Dana-Farber Cancer Institute discloses CDK7 inhibitors

Syros Pharmaceuticals and Paraza Pharma patent CDK7 inhibitors

The Blanchette Rockefeller Neurosciences Institute patents PKC-epsilon activators

Generon's F-652 cleared to enter phase II for acute graft-versus-host disease

Baxter submits European MAA for MM-398 for pancreatic cancer

European orphan drug designation for Makindus' MI-100 in Stargardt's disease

Dosing begins in Nigerian bridging study of Lodonal for HIV/AIDS

New phase II trial investigates Luminate for non-proliferative diabetic retinopathy

AEOL-10150 doubles survival in primate model of radiation-induced lung injury

CytRx offers interim reports from phase Ib aldoxorubicin combination studies

ARVO news: First-in-human clinical study of RetinoStat in wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...